草药作为补充和替代疗法对COVID-19患者康复和临床结果的疗效:系统评价、荟萃分析和荟萃回归

IF 2.3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES Therapeutics and Clinical Risk Management Pub Date : 2023-01-01 DOI:10.2147/TCRM.S405507
Maria Komariah, Shakira Amirah, Sidik Maulana, Muhammad Fahd Abdurrahman, Kusman Ibrahim, Hesti Platini, Juan Alessandro Jeremis Maruli Nura Lele, Kelvin Kohar, Laili Rahayuwati, Mohd Khairul Zul Hasymi Firdaus
{"title":"草药作为补充和替代疗法对COVID-19患者康复和临床结果的疗效:系统评价、荟萃分析和荟萃回归","authors":"Maria Komariah,&nbsp;Shakira Amirah,&nbsp;Sidik Maulana,&nbsp;Muhammad Fahd Abdurrahman,&nbsp;Kusman Ibrahim,&nbsp;Hesti Platini,&nbsp;Juan Alessandro Jeremis Maruli Nura Lele,&nbsp;Kelvin Kohar,&nbsp;Laili Rahayuwati,&nbsp;Mohd Khairul Zul Hasymi Firdaus","doi":"10.2147/TCRM.S405507","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic continues, and this condition has caused many cases in various countries around the world, resulting in more than 6 million deaths worldwide. Herbal medicines can act as immunomodulators, anti-inflammatories, antioxidants, antimicrobials, and others depending on the type and content of the herbs used. Previous studies have shown that several types of herbs, such as <i>Echinacea purpurea, Curcumin or Turmeric, Nigella sativa, and Zingiber officinale</i>, have proven their effectiveness as herbal plants for COVID-19.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search through five databases, namely, PubMed, Scopus, Embase, Wiley, and ProQuest to assess the efficacy of phytopharmaceuticals until July 12, 2022. We used the Cochrane RoB 2.0 for the quality assessment of the study.</p><p><strong>Results: </strong>Phytopharmaceuticals significantly improved patients' recovery rate (OR = 3.54; <i>p</i> < 0.00001) and reduced deaths (OR = 0.24; <i>p</i> < 0.0001) compared to the control group. Phytopharmaceuticals also performed as a protective factor for COVID-19 clinical symptoms, such as dyspnea (OR = 0.42; <i>p</i> < 0.05) and myalgia (OR = 0.31; <i>p</i> = 0.02) compared to the control group. However, there is no statistically significant effect on cough (OR = 0.76; <i>p</i> = 0.61) and fever (OR = 0.60; <i>p</i> < 0.20). The results were not affected by patients' covariates [hypertension, diabetes mellitus, and cardiovascular diseases (meta-regression <i>p</i> > 0.05)].</p><p><strong>Conclusion: </strong>Herbal medicine has the potential as an adjuvant therapy in the management of COVID-19.</p>","PeriodicalId":48769,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/8e/tcrm-19-611.PMC10362865.pdf","citationCount":"1","resultStr":"{\"title\":\"The Efficacy of Herbs as Complementary and Alternative Therapy in Recovery and Clinical Outcome Among People with COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression.\",\"authors\":\"Maria Komariah,&nbsp;Shakira Amirah,&nbsp;Sidik Maulana,&nbsp;Muhammad Fahd Abdurrahman,&nbsp;Kusman Ibrahim,&nbsp;Hesti Platini,&nbsp;Juan Alessandro Jeremis Maruli Nura Lele,&nbsp;Kelvin Kohar,&nbsp;Laili Rahayuwati,&nbsp;Mohd Khairul Zul Hasymi Firdaus\",\"doi\":\"10.2147/TCRM.S405507\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The COVID-19 pandemic continues, and this condition has caused many cases in various countries around the world, resulting in more than 6 million deaths worldwide. Herbal medicines can act as immunomodulators, anti-inflammatories, antioxidants, antimicrobials, and others depending on the type and content of the herbs used. Previous studies have shown that several types of herbs, such as <i>Echinacea purpurea, Curcumin or Turmeric, Nigella sativa, and Zingiber officinale</i>, have proven their effectiveness as herbal plants for COVID-19.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search through five databases, namely, PubMed, Scopus, Embase, Wiley, and ProQuest to assess the efficacy of phytopharmaceuticals until July 12, 2022. We used the Cochrane RoB 2.0 for the quality assessment of the study.</p><p><strong>Results: </strong>Phytopharmaceuticals significantly improved patients' recovery rate (OR = 3.54; <i>p</i> < 0.00001) and reduced deaths (OR = 0.24; <i>p</i> < 0.0001) compared to the control group. Phytopharmaceuticals also performed as a protective factor for COVID-19 clinical symptoms, such as dyspnea (OR = 0.42; <i>p</i> < 0.05) and myalgia (OR = 0.31; <i>p</i> = 0.02) compared to the control group. However, there is no statistically significant effect on cough (OR = 0.76; <i>p</i> = 0.61) and fever (OR = 0.60; <i>p</i> < 0.20). The results were not affected by patients' covariates [hypertension, diabetes mellitus, and cardiovascular diseases (meta-regression <i>p</i> > 0.05)].</p><p><strong>Conclusion: </strong>Herbal medicine has the potential as an adjuvant therapy in the management of COVID-19.</p>\",\"PeriodicalId\":48769,\"journal\":{\"name\":\"Therapeutics and Clinical Risk Management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/23/8e/tcrm-19-611.PMC10362865.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutics and Clinical Risk Management\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/TCRM.S405507\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S405507","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 1

摘要

背景:COVID-19大流行仍在继续,这种情况在世界各国造成了许多病例,导致全球600多万人死亡。草药可以作为免疫调节剂、抗炎药、抗氧化剂、抗菌剂和其他取决于草药的类型和含量。之前的研究表明,紫锥菊、姜黄素或姜黄、黑草和生姜等几种草药已被证明是治疗COVID-19的有效草药。方法:截至2022年7月12日,我们通过PubMed、Scopus、Embase、Wiley、ProQuest等5个数据库进行了全面的文献检索,评估植物药的疗效。我们使用Cochrane RoB 2.0对研究进行质量评估。结果:植物药显著提高患者治愈率(OR = 3.54;p < 0.00001),死亡率降低(OR = 0.24;P < 0.0001)。植物药也是COVID-19临床症状的保护因素,如呼吸困难(OR = 0.42;p < 0.05)和肌痛(OR = 0.31;P = 0.02)。但对咳嗽无统计学意义(OR = 0.76;p = 0.61)和发热(OR = 0.60;P < 0.20)。结果不受患者协变量[高血压、糖尿病、心血管疾病]的影响(meta-regression p > 0.05)。结论:中药作为新型冠状病毒肺炎的辅助治疗手段具有一定的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Efficacy of Herbs as Complementary and Alternative Therapy in Recovery and Clinical Outcome Among People with COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression.

Background: The COVID-19 pandemic continues, and this condition has caused many cases in various countries around the world, resulting in more than 6 million deaths worldwide. Herbal medicines can act as immunomodulators, anti-inflammatories, antioxidants, antimicrobials, and others depending on the type and content of the herbs used. Previous studies have shown that several types of herbs, such as Echinacea purpurea, Curcumin or Turmeric, Nigella sativa, and Zingiber officinale, have proven their effectiveness as herbal plants for COVID-19.

Methods: We conducted a comprehensive literature search through five databases, namely, PubMed, Scopus, Embase, Wiley, and ProQuest to assess the efficacy of phytopharmaceuticals until July 12, 2022. We used the Cochrane RoB 2.0 for the quality assessment of the study.

Results: Phytopharmaceuticals significantly improved patients' recovery rate (OR = 3.54; p < 0.00001) and reduced deaths (OR = 0.24; p < 0.0001) compared to the control group. Phytopharmaceuticals also performed as a protective factor for COVID-19 clinical symptoms, such as dyspnea (OR = 0.42; p < 0.05) and myalgia (OR = 0.31; p = 0.02) compared to the control group. However, there is no statistically significant effect on cough (OR = 0.76; p = 0.61) and fever (OR = 0.60; p < 0.20). The results were not affected by patients' covariates [hypertension, diabetes mellitus, and cardiovascular diseases (meta-regression p > 0.05)].

Conclusion: Herbal medicine has the potential as an adjuvant therapy in the management of COVID-19.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutics and Clinical Risk Management
Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-
CiteScore
4.80
自引率
3.60%
发文量
139
审稿时长
16 weeks
期刊介绍: Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.
期刊最新文献
The Etiologic Landscape of Lymphoproliferation in Childhood: Proposal for a Diagnostic Approach Exploring from Infections to Inborn Errors of Immunity and Metabolic Diseases Emerging Treatment Options for Myelofibrosis: Focus on Anemia. Factors Affecting Radial Artery Occlusion After Right Transradial Artery Catheterization for Coronary Intervention and Procedures. Effect of Tricalcium Phosphate on Healing of Non-Unions: An Observational Study of over 400 Non-Unions. Discontinuation of Antidepressants in Older Adults: A Literature Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1